- ・Target molecules or drug discovery lead compounds aiming to create NASH therapeutics.
- ・It is desirable that the mechanism of action should have scientific evidence suggestive of fibrosis degeneration.
•The purpose of collecting personal data is to consider and investigate contents, and to contact and respond to contact persons.
•The personal data may be transferred to database located in our company’s affiliates in Japan, US, Singapore, and Taiwan, as well as partnering companies of those affiliates. Although there is the absence of an adequacy decision from the European Commission to those countries and the region listed above, our company ensures to managepersonal data in an adequate way.
•Individual who provides personal information has the right to make a subject access request, rectification request for inaccurate personal data, and request for restriction on data processing. The contact information of the dedicated department is email@example.com . Moreover, if there are any complaints regarding our company’s way of processing of personal data, you have the right to lodge a complaint with the relevant supervisory authority or our company’s dedicated hotline. Finally, you have the right to withdraw your consent at any time under the applicable regulations, and it does not affect the lawfulness of processing or transferring based on consent before its withdrawal.
Please contact the following for any questions regarding this matter.
Personal Information Protection Officer
Head of the Legal Department, Shionogi & Co., Ltd.
1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan
Tel: +81-6-6209-6807 (Personal Information Hotline)
Reception Hours: 9:00 – 12:00, 13:00 – 17:00 (JP time)
(Closed on Saturdays, Sundays and public and company holidays)
Please tick the box below if you agree to the terms indicated above in regard to processing and transferring of personal data.